BAX vs INFU
BAX: Baxter International is a leading medical technology company delivering critical life-sustaining therapies for patients with complex medical conditions in hospitals and at home. INFU: A national healthcare service provider facilitating clinic-to-home infusion therapy through durable medical equipment rental, sales, and comprehensive patient support services.
Side-by-side fundamentals
| Metric | BAX | INFU | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $24.51 | $14.23 | |
| Market cap | $12.7B | $283M | |
| P/E as of 2026-10-20 | n/a | 35.57 | |
| Net margin FY2025, SEC XBRL | -8.5% | +4.6% | INFU higher |
| Gross margin FY2025, SEC XBRL | +30.1% | +56.0% | INFU higher |
| Operating margin FY2025, SEC XBRL | -2.7% | +8.3% | INFU higher |
| ROE FY2025, SEC XBRL | -15.7% | +11.6% | INFU higher |
| ROA FY2025, SEC XBRL | -4.8% | +6.6% | INFU higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 0.35 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +5.7% | +6.4% | INFU higher |
| Revenue CAGR (3y) SEC XBRL | +3.8% | +9.3% | INFU higher |
| Dividend yield as of 2026-09-03 | +0.2% | n/a | |
| Dividend streak (yrs) SEC XBRL | 1 | 0 | BAX higher |
| Beta as of 2026-09-03 | 0.92 | 1.13 | |
| 1-year return as of 2026-10-20 close | +6.0% | +48.2% | INFU higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.